BLIS Technologies (BLT) H2 2025 earnings summary

Executive summary

• Revenue grew 10% year-over-year to $12.6m, driven by finished product sales and B2C channel expansion.

• EBITDA increased 26% to $1.0m, exceeding guidance, with net profit after tax up 30% to $0.8m.

• Strong cash position with $9.7m at year-end, supported by a 70% increase in operating cash flow to $1.8m.

• Navigated intellectual property challenges and advanced China regulatory approvals for key products.

Financial highlights

• Revenue: $12.6m (up 10% year-over-year); EBITDA: $1.0m (up 26%); NPAT: $0.8m (up 30%).

• Cash generated from operations: $1.8m (up 70%); cash and short-term deposits: $9.7m.

• Gross margin and contribution margins remained strong; EPS increased to 0.07 cents.

• Return on equity improved to 6.8%; cash conversion ratio at 178.4%.

Outlook and guidance

• Entering FY26 with cautious optimism amid mixed macroeconomic conditions.

• Focus on revenue growth in key countries, innovation in oral health, and regulatory advancement.

• New fermentation partner to address supply chain constraints, with additional supply expected in 2026.